Invention Grant
- Patent Title: Prevention or treatment agent for hepatic fibrosis
-
Application No.: US15615131Application Date: 2017-06-06
-
Publication No.: US10265331B2Publication Date: 2019-04-23
- Inventor: Takenao Odagami , Hiroyuki Kouji , Michinori Kohara
- Applicant: PRISM Pharma Co., Ltd.
- Applicant Address: JP Kanagawa
- Assignee: PRISM Pharma Co., Ltd.
- Current Assignee: PRISM Pharma Co., Ltd.
- Current Assignee Address: JP Kanagawa
- Agency: Scully Scott Murphy and Presser
- Priority: JP2012-270987 20121212
- Main IPC: A61K31/675
- IPC: A61K31/675 ; A61K31/5365 ; A61K45/06 ; A61K31/53
Abstract:
CBP/β-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis.
Public/Granted literature
- US20170266212A1 PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS Public/Granted day:2017-09-21
Information query
